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Noroviruses are now recognized as the leading cause of acute gastroenteritis across the age 
spectrum. New global estimates of the norovirus disease burden highlight the specific 
populations most affected and potential targets for prevention strategies. As traditional 
infection control and food hygiene measures may be inadequate to fully control norovirus 
disease, vaccines are an appealing option. Initial trials of candidate vaccines have 
demonstrated only modest efficacy, but show promise that norovirus prevention through 
vaccination is possible. Key issues that require further study include duration of immunity, 
degree of cross-protection, and efficacy in target populations. While initial introduction of 
norovirus vaccines is likely to occur in developed countries, the greatest public health 
burden and thus potential impact of such vaccines is in developing countries.
Recognition of the public health impact of noroviruses has increased dramatically in the past 
two decades through the application of molecular-based diagnostics. In many developed 
countries, noroviruses are now recognized to be the leading cause of acute gastroenteritis 
across the age spectrum and the leading cause of foodborne disease, including outbreaks [1]. 
In the United States, for example, noroviruses are responsible for approximately 20 million 
episodes of acute gastroenteritis annually, with about 70,000 hospitalizations and up to 800 
deaths, mostly in the elderly [2]. Furthermore, following the decline in rotavirus disease 
after vaccine introduction in 2006, noroviruses have replaced rotavirus as the leading cause 
of severe gastroenteritis in US children aged <5 years [3]. However, from a global 
perspective, the greatest public health burden from noroviruses is undoubtedly exacted upon 
developing countries, where diarrheal diseases remain among the leading causes of death 
[4]. A recent systematic review concluded that norovirus was associated with 18% of all 
acute gastroenteritis worldwide [5]. Of 175 studies included in the review, 147 (84%) were 
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published since 2008, among which 94 (64%) were conducted in developing countries. 
While data specifically on norovirus incidence and disease burden from these countries are 
more limited and some studies have suggested that detection of noroviruses may not be 
causally associated with illness in all cases [6,7], this review demonstrates the increased 
effort in recent years to better understand the public health impact of noroviruses globally so 
that we may better address it.
In 2015, the World Health Organization (WHO) released the first global estimates of the 
burden of foodborne disease [8]. Noroviruses were identified as the leading global cause of 
foodborne illness and among the top five causes of foodborne disease–associated death. 
Worldwide, the WHO estimated that noroviruses annually cause 685 million cases of 
diarrhea (95% confidence interval [CI]: 491 million–1.1 billion) and 212,489 deaths (95% 
CI: 160,595–278,420), with ∼85% of these illnesses and ∼99% of the deaths occurring in 
developing countries [9]. The Southeast Asia and Africa regions alone accounted for ∼85% 
of all norovirus deaths. Much of this illness was in older children, adults, and the elderly 
with only ∼30% of norovirus illnesses and ∼25% of norovirus deaths in children aged <5 
years. Of note, in developed countries with prolonged life expectancy, most of the deaths 
were in the elderly, whereas in low-income countries, much of the disease and death were in 
children aged <5 years. In the Africa region, for example, children aged <5 years comprised 
∼60% of all norovirus cases. These landmark WHO estimates provide an important 
opportunity to assess currently available prevention strategies for noroviruses, which have 
traditionally focused on infection control and food hygiene. However, while noroviruses are 
the leading cause of foodborne disease worldwide, direct exposure to contaminated food is 
estimated to account for <20% of all norovirus cases [10,11]. As such, improvements in 
food safety without addressing the underlying transmission in human population reservoirs 
may be inadequate in fully controlling norovirus disease. Vaccines may, therefore, provide a 
useful tool for effectively addressing the global burden of noroviruses.
Multiple norovirus vaccines are currently in the pipeline, although the one that is the furthest 
along in clinical development is an intramuscular bivalent genogroup GI.1/GII.4 virus-like 
particle (VLP) formulation. A clinical trial among healthy adults given this vaccine and then 
challenged with heterovariant GII.4 virus failed to demonstrate significant reduction in the 
overall incidence of norovirus disease (22% efficacy, 95% CI: −44–58%); however, the 
vaccine did significantly reduce norovirus disease severity as measured by a modified 
Vesikari score [12]. Additionally, vaccine recipients tended to clear the virus more rapidly 
than those receiving placebo, suggesting that vaccine may afford some additional benefit in 
terms of subsequent transmission risk. An initial proof-of-concept trial using an intranasal 
monovalent genogroup GI.1 VLP formulation followed by homologous viral challenge had 
demonstrated somewhat better efficacy, with 47% (95% CI: 15–67%) reduction in norovirus 
disease incidence and 26% (95% CI: 1–45%) reduction in norovirus infection [13]. While 
these early trial results demonstrate room for improvement in vaccine performance, they 
provide hope that in the future a vaccine could reduce the global burden of norovirus 
disease.
Several key questions remain, however, such as the degree of cross-protection given the 
diversity of noroviruses and continual emergence of new strains and the duration of vaccine-
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induced immunity. While the majority of norovirus disease worldwide is caused by a single 
genotype, GII.4 [11,14], new variants within this group have emerged every 2–4 years over 
the last two decades, apparently driven by escape from population immunity [15]. These 
‘GII.4 du jour’ strains generally replace their predecessors but co-circulate with up to 30 
other norovirus genotypes, which may be antigenically distinct [16]. The selective pressures 
behind these dynamics indicate that norovirus infection does confer at least some acquired 
immunity, suggesting that vaccine-induced immunity may likewise be possible. However, an 
effective norovirus vaccine may require multiple constituent antigens as well as periodic 
reformulation to adapt to changes in molecular epidemiology. Additionally, immunity 
following norovirus infection is not lifelong and estimates of the duration of immunity vary 
widely from 6 months to 9 years [17,18]. Assuming a vaccine affords similar duration of 
protection as natural infection, vaccine boosters may be necessary given the impacts of 
norovirus disease across the age spectrum, particularly among young children and the 
elderly. Potential issues with immunosenescence in the elderly and other host-specific 
factors may also impact vaccine performance and need to be assessed through further study.
Additional data addressing issues of immunity, along with more refined estimates of disease 
burden, can help inform future development of effective norovirus vaccine programs, 
including the specific groups that should be targeted. Given the highly infectious nature of 
noroviruses, their propensity for causing outbreaks, and their primary reservoir being in 
humans, it is possible that a vaccine intervention could afford both direct benefit to vaccine 
recipients and indirect benefits to others through prevention of downstream transmission. 
For example, a vaccine that directly reduces norovirus incidence in children, who have the 
highest rates of norovirus disease, may help decrease exposure and subsequent severe 
outcomes among the elderly, as has been observed following rotavirus vaccine introduction 
[19]. However, more data are needed on potential vaccine efficacy in different age groups, as 
well as the possible role of herd protection and other transmission dynamics. Other potential 
targets for norovirus vaccines may be prioritized due to high disease burden (e.g. travelers 
and military), transmission risk to others (e.g. health-care workers and food handlers), or 
both (e.g. immunocompromised patients) [20]. While initial licensure and introduction of 
norovirus vaccines is likely to occur in developed countries, their greatest potential benefit 
lies in developing countries. The collective body of science on noroviruses that has amassed 
over the last two decades demonstrates a global public health need for norovirus vaccines 
and serves as a call for further efforts to address key remaining issues so that their potential 
benefits, particularly to the most impoverished countries of the world, may soon be realized.
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